HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second quarter ended June 30, 2023. “Looking ahead, we remain focused on gaining clearance for […]
Financial
HeartBeam Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has reported its financial and operational results for the second quarter ended […]
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023. “We are dedicated to bringing life-changing, once-and-done […]
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update. “We are excited about this […]
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 10, 2023 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a clinical and corporate update. “The remainder of 2023 represents a transformative time for the […]
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PONTE VEDRA, Fla., Aug. 10, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the […]
CorVista Health Welcomes Dr. Tim Attebery as New Board Member
WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the election of Dr. Tim Attebery to its Board of Directors. “Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors” […]
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended […]
Ionis reports second quarter 2023 financial results
CARLSBAD, Calif., Aug. 9, 2023 /PRNewswire/ — – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the second quarter of 2023. Financial results are summarized below: Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 (amounts in millions) Total revenue $188 $134 $319 $276 […]
Shockwave Medical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023. Recent Highlights Recognized revenue of $180.2 million for […]
Recent
Popular
- No commented posts yet